IE 11 is a very old Browser and it`s not supported on this site
Business Report Performance

Performance/Multi-year comparison

Indexed performance since launch

BB Biotech AG (SIX)-CHF


Rolling performance

 

 

SHARE

 

NAV

 

NBI TR

31.03.2021 – 31.03.2022

 

(16.7%)

 

(23.6%)

 

(13.0%)

31.03.2020 – 31.03.2021

 

63.3%

 

67.9%

 

36.7%

31.03.2019 – 31.03.2020

 

(19.5%)

 

(26.6%)

 

(5.8%)

29.03.2018 – 29.03.2019

 

8.3%

 

11.7%

 

9.5%

31.03.2017 – 29.03.2018

 

24.3%

 

10.2%

 

5.1%

Annual performance

 

 

SHARE

 

NAV

 

NBI TR

2021

 

8.3%

 

(11.5%)

 

3.0%

2020

 

19.3%

 

24.3%

 

15.8%

2019

 

18.5%

 

23.4%

 

23.0%

2018

 

(5.2%)

 

(14.5%)

 

(8.0%)

2017

 

22.9%

 

23.4%

 

16.4%

Cumulated performance

 

 

SHARE

 

NAV

 

NBI TR

YTD

 

(11.3%)

 

(9.0%)

 

(10.6%)

1 year

 

(16.7%)

 

(23.6%)

 

(13.0%)

3 years

 

9.5%

 

(5.8%)

 

12.0%

5 years

 

47.4%

 

15.9%

 

28.9%

since inception 1)

 

2 735%

 

2 063%

 

1 238%

1 09.11.1993

Annualized performance

 

 

SHARE

 

NAV

 

NBI TR

1 year

 

(16.7%)

 

(23.6%)

 

(13.0%)

3 years

 

3.1%

 

(2.0%)

 

3.8%

5 years

 

8.1%

 

3.0%

 

5.2%

since inception 1)

 

12.5%

 

11.4%

 

9.6%

1 09.11.1993

BB BIOTECH AG (XETRA)-EUR


Rolling performance

 

 

SHARE

 

NAV

 

NBI TR

31.03.2021 – 31.03.2022

 

(9.4%)

 

(17.2%)

 

(5.8%)

31.03.2020 – 31.03.2021

 

58.5%

 

60.7%

 

30.8%

31.03.2019 – 31.03.2020

 

(16.2%)

 

(22.6%)

 

(0.6%)

29.03.2018 – 29.03.2019

 

14.5%

 

17.8%

 

15.3%

31.03.2017 – 29.03.2018

 

13.1%

 

0.0%

 

(4.4%)

Annual performance

 

 

SHARE

 

NAV

 

NBI TR

2021

 

13.3%

 

(7.8%)

 

7.4%

2020

 

18.1%

 

24.8%

 

16.1%

2019

 

23.4%

 

28.1%

 

27.6%

2018

 

(2.2%)

 

(11.1%)

 

(4.3%)

2017

 

12.9%

 

12.5%

 

6.7%

Cumulated performance

31.03.2022

 

 

SHARE

 

NAV

 

NBI TR

YTD

 

(8.6%)

 

(7.6%)

 

(9.2%)

1 year

 

(9.4%)

 

(17.2%)

 

(5.8%)

3 years

 

20.3%

 

3.0%

 

22.5%

5 years

 

55.8%

 

21.3%

 

34.9%

since inception 1)

 

2 326%

 

1 738%

 

1 328%

1 10.12.1997

Annualized performance

31.03.2022

 

 

SHARE

 

NAV

 

NBI TR

1 year

 

(9.4%)

 

(17.2%)

 

(5.8%)

3 years

 

6.3%

 

1.0%

 

7.0%

5 years

 

9.3%

 

3.9%

 

6.2%

since inception 1)

 

14.0%

 

12.7%

 

11.6%

1 10.12.1997

BB BIOTECH AG (MILAN)-EUR


Rolling performance

 

 

SHARE

 

NAV

 

NBI TR

31.03.2021 – 31.03.2022

 

(9.1%)

 

(17.2%)

 

(5.8%)

31.03.2020 – 31.03.2021

 

57.6%

 

60.7%

 

30.8%

31.03.2019 – 31.03.2020

 

(14.7%)

 

(22.6%)

 

(0.6%)

29.03.2018 – 29.03.2019

 

13.0%

 

17.8%

 

15.3%

31.03.2017 – 29.03.2018

 

12.8%

 

0.0%

 

(4.4%)

Annual performance

 

 

SHARE

 

NAV

 

NBI TR

2021

 

13.0%

 

(7.8%)

 

7.4%

2020

 

19.7%

 

24.8%

 

16.1%

2019

 

22.6%

 

28.1%

 

27.6%

2018

 

(1.3%)

 

(11.1%)

 

(4.3%)

2017

 

12.2%

 

12.5%

 

6.7%

Cumulated performance

31.03.2022

 

 

SHARE

 

NAV

 

NBI TR

YTD

 

(9.0%)

 

(7.6%)

 

(9.2%)

1 year

 

(9.1%)

 

(17.2%)

 

(5.8%)

3 years

 

22.1%

 

3.0%

 

22.5%

5 years

 

55.6%

 

21.3%

 

34.9%

since inception 1)

 

461%

 

324%

 

170%

1 19.10.2000

Annualized performance

31.03.2022

 

 

SHARE

 

NAV

 

NBI TR

1 year

 

(9.1%)

 

(17.2%)

 

(5.8%)

3 years

 

6.9%

 

1.0%

 

7.0%

5 years

 

9.2%

 

3.9%

 

6.2%

since inception 1)

 

8.4%

 

7.0%

 

4.7%

1 19.10.2000

Multi-year comparison

 

 

31.03.2022

 

2021

 

2020

 

2019

 

2018

 

 

Market capitalization at the end of the period (in CHF mn)

 

3 584.4

 

4 274.1

 

4 107.9

 

3 670.3

 

3 235.4

 

highchart-toggle

Net Asset Value at the end of the period (in CHF mn)

 

2 760.9

 

3 283.5

 

3 887.5

 

3 393.0

 

2 884.5

 

highchart-toggle

Number of shares (in mn)

 

55.4

 

55.4

 

55.4

 

55.4

 

55.4

 

highchart-toggle

Trading volume (in CHF mn)

 

640.9

 

2 101.0

 

2 315.6

 

2 004.2

 

2 610.7

 

highchart-toggle

Profit/(loss) (in CHF mn)

 

(299.9)

 

(404.8)

 

691.2

 

677.4

 

(471.3)

 

highchart-toggle

Closing price at the end of the period in CHF

 

64.70

 

77.15

 

74.15

 

66.25

 

58.40

 

highchart-toggle

Closing price (G) at the end of the period in EUR

 

63.95

 

74.05

 

68.00

 

61.40

 

52.00

 

highchart-toggle

Closing price (I) at the end of the period in EUR

 

63.95

 

74.40

 

68.50

 

61.00

 

52.00

 

highchart-toggle

Stock performance (incl. distributions) 1)

 

(11.3%)

 

8.3%

 

19.3%

 

18.5%

 

(5.2%)

 

highchart-toggle

High/low share price in CHF

 

78.15/60.50

 

92.20/73.40

 

74.70/45.44

 

73.20/59.35

 

74.10/56.10

 

highchart-toggle

High/low share price in EUR

 

75.40/58.00

 

86.20/67.80

 

69.00/43.04

 

64.70/52.10

 

64.80/48.60

 

highchart-toggle

Premium/(discount) (annual average)

 

32.2%

 

19.5%

 

9.2%

 

11.8%

 

9.7%

 

highchart-toggle

Dividend in CHF

 

N.A.

 

3.85

 

3.60

 

3.40

 

3.05

 

highchart-toggle

Degree of investment (quarterly figures)

 

113.0%

 

108.6%

 

106.8%

 

109.1%

 

108.4%

 

highchart-toggle

Total Expense Ratio (TER) p.a. 2)

 

1.23%

 

1.22%

 

1.25%

 

1.26%

 

1.25%

 

highchart-toggle

1 All figures in CHF %, total return-methodology

2 Based on market capitalization

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience. Use of cookies & disclaimer